TriSalus Life Sciences (TLSIW) Payables (2020 - 2026)

TriSalus Life Sciences has reported Payables for 7 years, with the latest figure at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 50.82% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.2 million (up 50.82% YoY), and the FY2025 full-year result was $3.0 million, up 32.01% from the prior year.
• Payables for Q1 2026 stood at $4.2 million, up from $3.0 million in the prior quarter.
• The five-year high for Payables was $5.9 million in Q4 2022, with the low at $1.4 million in Q3 2024.
• Historically, Payables has averaged $2.8 million across 5 years, with a median of $2.3 million in 2024.
• Annual changes were most pronounced in 2022 — Payables jumped 382.82% — and 2024, when it sank 53.43%.
• TriSalus Life Sciences' Payables stood at $5.9 million in 2022, then tumbled by 42.44% to $3.4 million in 2023, then sank by 32.94% to $2.3 million in 2024, then soared by 32.01% to $3.0 million in 2025, then jumped by 40.97% to $4.2 million in 2026.
• The last three Payables figures came in at $4.2 million (Q1 2026), $3.0 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.